Skip to main content
SpringerLink
Log in

Hepatic Encephalopathy in Liver Cirrhosis

  • Chapter
  • First Online:
The Evolving Landscape of Liver Cirrhosis Management

  • 514 Accesses

Abstract

Hepatic encephalopathy (HE) is the most severe and often fatal complication of liver cirrhosis. Intestine-derived neurotoxic substances, such as ammonia, are believed to be the cause of HE. As the results from hepatocellular dysfunction or portosystemic shunt associated with liver cirrhosis, those toxins, which should be detoxified in the liver, flow into the systemic circulation and perturb the brain function. The symptoms of HE include consciousness disorders that range from mild disorders, such as minimal hepatic encephalopathy, to severe disorders that result in deep coma. HE associated with liver cirrhosis develops when some additional triggers overlie liver failure or portosystemic shunt, such as constipation, a high-protein diet, and gastrointestinal bleeding, which are the therapeutic targets of medical treatment. Synthetic disaccharides and rifaximin are used to suppress intestinal ammonia production, and BCAA and zinc are used to support ammonia detoxification in the liver or muscle.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European. Hepatology. 2014;60(2):715–34.

    Article  Google Scholar 

  2. Kawaguchi T, Konishi M, Kato A, Kato M, Kooka Y, Sawara K, Endo R, Torimura T, Suzuki K, Takikawa Y. Updating the neuropsychological test system in Japan for the elderly and in a modern touch screen tablet society by resetting the cut-off values. Hepatol Res. 2017;47(12):1335–9.

    Article  Google Scholar 

  3. Kato A, Tanaka H, Kawaguchi T, et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study. Hepatol Res. 2013;43(5):452–8.

    Article  CAS  Google Scholar 

  4. Kaneta H, Kato A, Suzuki K. Clinical manifestation of subclinical hepatic encephalopathy in patients with non-alcoholic cirrhosis. Hepatol Jpn. 1994;35:167–71.

    Google Scholar 

  5. Groeneweg M, Quero JC, De Bruijin I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45–9.

    Article  CAS  Google Scholar 

  6. Schomerous H, Hamster W, Blunck H, et al. Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci. 1981;26(7):622–30.

    Article  Google Scholar 

  7. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16(5):531–5.

    Article  CAS  Google Scholar 

  8. Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis. 2013;28(1):1–5.

    Article  CAS  Google Scholar 

  9. Kooka Y, Sawara K, Endo R, et al. Brain metabolism in minimal hepatic encephalopathy assessed by 3.0-Tesla magnetic resonance spectroscopy. Hepatol Res. 2016;46:269–76.

    Article  Google Scholar 

  10. Norenberg MD. A light and electron microscopic study of experimental portal-systemic (ammonia) encephalopathy. Progression and reversal of the disorder. Lab Investig. 1977;36(6):618–27.

    CAS  PubMed  Google Scholar 

  11. Hindfelt B, Plum F, Duffy TE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest. 1977;59(3):386–96.

    Article  CAS  Google Scholar 

  12. Bessaman SP, Bessaman AN. The cerebral and peripheral uptake of ammonia in liver disease with an hypothesis for the mechanism of hepatic coma. J Clin Invest. 1955;34(4):622–8.

    Article  Google Scholar 

  13. Butterworth RF, Vaquero J. Hepatic encephalopathy. In: Aris I, Alter H, Boyer J, Cohen D, Feusto N, Shafritz D, Wollkoff A, editors. The liver: biology and Pathology. 5th ed. Hoboken: Wiley; 2009.

    Google Scholar 

  14. Lai JC, Cooper AJ. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J Neurochem. 1986;47(5):1376–86.

    Article  CAS  Google Scholar 

  15. O’Keefe SJ, Abraham R, El-Zayadi A, Marshall W, Davis M, Williams R. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic oxidation capacity. Gastroenterology. 1981;81(6):1017–24.

    PubMed  Google Scholar 

  16. Butterworth RF. Pathophysiology of hepatic encephalopathy: the concept of synergism. Hepatol Res. 2008;8(Suppl.1):S116–21.

    Article  Google Scholar 

  17. Amodio P, Montagnese S, Gatta A, et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004;19(3-4):253–67.

    Article  Google Scholar 

  18. Kato A, Kato M, Ishii H, et al. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria-multicenter collaborative study in Japanese. Hepatol Res. 2004;30(2):71–8.

    Article  Google Scholar 

  19. Iwasa M, Takei Y. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia. Hepatol Res. 2015;45:1155–62.

    Article  CAS  Google Scholar 

  20. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51–8.

    Article  CAS  Google Scholar 

  21. Suzuki K, Endo R, Takikawa Y, et al. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48(6):411–23.

    Article  CAS  Google Scholar 

  22. Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450–5.

    Article  CAS  Google Scholar 

  23. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  Google Scholar 

  24. Patidar KR, Bajaj JS, et al. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28:307–12.

    Article  CAS  Google Scholar 

  25. Gluud LL, Dam G, Borre M, et al. Oral branched-chain amino acids have a beneficial effect on manifestation of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143:1263–8.

    Article  CAS  Google Scholar 

  26. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.

    Article  CAS  Google Scholar 

  27. Katayama K, Saito M, Sawara K, et al. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition. 2014;30(11-12):1409–14.

    Article  CAS  Google Scholar 

  28. Takuma Y, Nouso K, Makino K, et al. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32(9):1080–90.

    Article  CAS  Google Scholar 

  29. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008;20(6):506–11.

    Article  CAS  Google Scholar 

  30. Malaguarnera PG, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastoenterol. 2005;11:7197–202.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan

    Yasuhiro Takikawa, Takuro Sato & Keisuke Kakisaka

Authors
  1. Yasuhiro Takikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takuro Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keisuke Kakisaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhiro Takikawa .

Editor information

Editors and Affiliations

  1. Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan

    Hitoshi Yoshiji

  2. Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan

    Kosuke Kaji

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Takikawa, Y., Sato, T., Kakisaka, K. (2019). Hepatic Encephalopathy in Liver Cirrhosis. In: Yoshiji, H., Kaji, K. (eds) The Evolving Landscape of Liver Cirrhosis Management. Springer, Singapore. https://doi.org/10.1007/978-981-13-7979-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7979-6_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7663-4

  • Online ISBN: 978-981-13-7979-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation